Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 594

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Monoamine neurocircuitry in depression and strategies for new treatments

Hamon, Michel, Blier, Pierre·2013·Progress in Neuro-Psychopharmacology and Biological Psychiatry

Abstract

Extensive studies showed that monoaminergic neurotransmission that involves serotonin (5-HT), norepinephrine (NE) and dopamine (DA) exerts major influence on brain circuits concerned by the regulation of mood, reactivity to psychological stress, self-control, motivation, drive, and cognitive performance. Antidepressants targeting monoamines directly affect the functional tone of these circuits, notably in limbic and frontocortical areas, and evidence has been provided that this action plays a key role in their therapeutic efficacy. Indeed, at least some of functional changes detected by functional magnetic resonance imaging in emotion- and cognitive-related circuits such as the one involving limbic-cortical-striatal-pallidal-thalamic connections in depressed patients can be reversed by monoamine-targeted antidepressants. However, antidepressants acting selectively on only one monoamine, such as selective inhibitors of 5-HT or NE reuptake, alleviate depression symptoms in a limited percentage of patients, and are poorly effective to prevent recurrence. Thorough investigations for the last 30 years allowed the demonstration of the existence of functional interactions between 5-HT, NE and DA systems, and the identification of the specific receptors involved. In particular, 5-HT systems were shown to exert negative influence on NE and DA systems through 5-HT2A and 5-HT2C receptor- mediated mechanisms, respectively. On the other hand, complex positive and negative influences of NE…

Overview

Integrity signals

Registry

Crossref · 10.1016/j.pnpbp.2013.04.009

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 37 references

Research works printed but not linked: 94

  1. Albert, 2010, Modifying 5-HT1A receptor gene expression as a new target for antidepressant therapy, Front Neurosci, 4, 1
  2. Albert, 2011, Transcriptional dysregulation of 5-HT1A autoreceptors in mental illness, Mol Brain, 4, 21, 10.1186/1756-6606-4-21 · DOI
  3. Anisman, 2008, Serotonin receptor subtype and p11 mRNA expression in stress-relevant brain regions of suicide and control subjects, J Psychiatry Neurosci, 33, 131
  4. Berman, 2000, Antidepressant effects of ketamine in depressed patients, Biol Psychiatry, 47, 351, 10.1016/S0006-3223(99)00230-9 · DOI · Paper page
  5. Bhagwagar, 2004, Persistent reduction in brain serotonin1A receptor binding in recovered depressed men measured by positron emission tomography with [11C]WAY-100635, Mol Psychiatry, 9, 386, 10.1038/sj.mp.4001401 · DOI · Paper page
  6. Blier, 1983, Electrophysiological investigations on the effect of zimelidine administration on serotonergic neurotransmission in the rat, J Neurosci, 3, 1270, 10.1523/JNEUROSCI.03-06-01270.1983 · DOI · Paper page
  7. Blier, 2003, Is there a role for 5-HT1A agonists in the treatment of depression?, Biol Psychiatry, 53, 193, 10.1016/S0006-3223(02)01643-8 · DOI · Paper page
  8. Blier, 2009, Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation, Eur Neuropsychopharmacol, 19, 457, 10.1016/j.euroneuro.2009.01.015 · DOI · Paper page
  9. Boldrini, 2008, Serotonin-1A autoreceptor binding in the dorsal raphe nucleus of depressed suicides, J Psychiatr Res, 42, 433, 10.1016/j.jpsychires.2007.05.004 · DOI · Paper page
  10. Bonnavion, 2010, Heterogeneous distribution of the serotonin 5-HT1A receptor mRNA in chemically identified neurons of the mouse rostral brainstem: implications for the role of serotonin in the regulation of wakefulness and REM sleep, J Comp Neurol, 518, 2744, 10.1002/cne.22331 · DOI
  11. Boothman, 2006, In vivo evidence that 5-HT2C receptors inhibit 5-HT neuronal activity via a GABAergic mechanism, Br J Pharmacol, 149, 861, 10.1038/sj.bjp.0706935 · DOI
  12. Bortolozzi, 2012, New antidepressant strategy based on acute siRNA silencing of 5-HT1A autoreceptors, Mol Psychiatry, 17, 567, 10.1038/mp.2012.52 · DOI
  13. Brodaty, 1993, Prognosis of depression in the elderly. A comparison with younger patients, Br J Psychiatry, 163, 589, 10.1192/bjp.163.5.589 · DOI
  14. Campbell, 2004, Lower hippocampal volume in patients suffering from depression: a meta-analysis, Am J Psychiatry, 161, 598, 10.1176/appi.ajp.161.4.598 · DOI · Paper page
  15. Cassel, 2006, Fluoxetine and cocaine induce the epigenetic factors MeCP2 and MBD1 in adult rat brain, Mol Pharmacol, 70, 487, 10.1124/mol.106.022301 · DOI · Paper page
  16. Coupland, 2005, Decreased prefrontal myo-inositol in major depressive disorder, Biol Psychiatry, 57, 1526, 10.1016/j.biopsych.2005.02.027 · DOI · Paper page
  17. Debonnel, 2007, Differential physiological effects of a low dose and high doses of venlafaxine in major depression, Int J Neuropsychopharmacol, 10, 51, 10.1017/S1461145705006413 · DOI
  18. De Deurwaerdère, 2004, Constitutive activity of the serotonin 2C receptor inhibits in vivo dopamine release in the rat striatum and nucleus accumbens, J Neurosci, 24, 3235, 10.1523/JNEUROSCI.0112-04.2004 · DOI · Paper page
  19. Delgado, 1999, Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: implications for the role of serotonin in the mechanism of antidepressant action, Biol Psychiatry, 46, 212, 10.1016/S0006-3223(99)00014-1 · DOI · Paper page
  20. Delgado, 2006, Depression: the case for a monoamine deficiency, J Clin Psychiatry, 61, 7
  21. Diazgranados, 2010, A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression, Arch Gen Psychiatry, 67, 793, 10.1001/archgenpsychiatry.2010.90 · DOI · Paper page
  22. Dremencov, 2009, Effects of sustained serotonin reuptake inhibition on the firing of dopamine neurons in the rat ventral tegmental area, J Psychiatry Neurosci, 34, 223
  23. Dremencov, 2007, Noradrenergic augmentation of escitalopram response by risperidone: electrophysiologic studies in the rat brain, Biol Psychiatry, 61, 671, 10.1016/j.biopsych.2006.05.015 · DOI
  24. Dziedzicka-Wasylewska, 2006, Effect of antidepressant drugs in mice lacking the norepinephrine transporter, Neuropsychopharmacology, 31, 2424, 10.1038/sj.npp.1301064 · DOI
  25. Fabre, 2000, Altered expression and functions of serotonin 5-HT1A and 5-HT1B receptors in knock-out mice lacking the 5-HT transporter, Eur J Neurosci, 12, 2299, 10.1046/j.1460-9568.2000.00126.x · DOI · Paper page
  26. Guiard, 2011, Characterization of the electrophysiological properties of triple reuptake inhibitors on monoaminergic neurons, Int J Neuropsychopharmacol, 14, 211, 10.1017/S1461145710000076 · DOI
  27. Guo, 2011, Abnormal neural activities in first-episode, treatment-naïve, short-illness-duration, and treatment-response patients with major depressive disorder: a resting-state fMRI study, J Affect Disord, 135, 326, 10.1016/j.jad.2011.06.048 · DOI
  28. Hammar, 2010, Enduring cognitive dysfunction in unipolar major depression: a test-retest study using the Stroop paradigm, Scand J Psychol, 51, 304
  29. Hamon, 2006, Pharmacological profile of antidepressants: a likely basis for their efficacy and side effects?, Eur Neuropsychopharmacol, 16, S625, 10.1016/S0924-977X(06)70008-6 · DOI
  30. Holtzheimer, 2011, Deep brain stimulation for psychiatric disorders, Annu Rev Neurosci, 34, 289, 10.1146/annurev-neuro-061010-113638 · DOI · Paper page
  31. Jacobsen, 2012, Deficient serotonin neurotransmission and depression-like serotonin biomarker alterations in tryptophan hydroxylase 2 (Tph2) loss-of-function mice, Mol Psychiatry, 17, 694, 10.1038/mp.2011.50 · DOI
  32. Judd, 2000, Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness?, Am J Psychiatry, 157, 1501, 10.1176/appi.ajp.157.9.1501 · DOI · Paper page
  33. Karg, 2011, The serotonin transporter promoter variant(5-HTTLPR), stress, and depression meta-analysis revisited: evidence of genetic moderation, Arch Gen Psychiatry, 68, 444, 10.1001/archgenpsychiatry.2010.189 · DOI · Paper page
  34. Kasper, 2009, Beyond the monoaminergic hypothesis: Agomelatine, a new antidepressant with an innovative mechanism of action, World J Biol Psychiatry, 10, 117, 10.1080/15622970902717024 · DOI
  35. Kennedy, 2001, Changes in regional brain glucose metabolism measured with positron emission tomography after paroxetine treatment of major depression, Am J Psychiatry, 158, 899, 10.1176/appi.ajp.158.6.899 · DOI · Paper page
  36. Kitaichi, 2010, Sertraline increases extracellular levels not only of serotonin, but also of dopamine in the nucleus accumbens and striatum of rats, Eur J Pharmacol, 647, 90, 10.1016/j.ejphar.2010.08.026 · DOI
  37. Koch, 2003, Comparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in rats, Neuropharmacology, 45, 935, 10.1016/S0028-3908(03)00268-5 · DOI
  38. Kondo, 2005, Differential connections of the perirhinal and parahippocampal cortex with the orbital and medial prefrontal networks in macaque monkeys, J Comp Neurol, 493, 479, 10.1002/cne.20796 · DOI · Paper page
  39. Lanfumey, 2004, 5-HT1 receptors, Curr Drug Targets - CNS Neurol Disord, 3, 1, 10.2174/1568007043482570 · DOI · Paper page
  40. Lanfumey, 2008, Corticosteroid-serotonin interactions in the neurobiological mechanisms of stress-related disorders, Neurosci Biobehav Rev, 32, 1174, 10.1016/j.neubiorev.2008.04.006 · DOI · Paper page
  41. Lesch, 1996, Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region, Science, 274, 1527, 10.1126/science.274.5292.1527 · DOI · Paper page
  42. Li, 2010, mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists, Science, 329, 959, 10.1126/science.1190287 · DOI · Paper page
  43. Lira, 2003, Altered depression-related behaviors and functional changes in the dorsal raphe nucleus of serotonin transporter-deficient mice, Biol Psychiatry, 54, 960, 10.1016/S0006-3223(03)00696-6 · DOI · Paper page
  44. Lisiecka, 2011, Neural correlates of treatment outcome in major depression, Int J Neuropsychopharmacol, 14, 521, 10.1017/S1461145710001513 · DOI
  45. Maciag, 2010, Reduced density of calbindin immunoreactive GABAergic neurons in the occipital cortex in major depression: relevance to neuroimaging studies, Biol Psychiatry, 67, 465, 10.1016/j.biopsych.2009.10.027 · DOI · Paper page
  46. Massart, 2012, Beyond the monoaminergic hypothesis: neuroplasticity and epigenetic changes in a transgenic mouse model of depression, Philos Trans R Soc Lond B Biol Sci, 367, 2485, 10.1098/rstb.2012.0212 · DOI · Paper page
  47. McKinnon, 2009, A meta-analysis examining clinical predictors of hippocampal volume in patients with major depressive disorder, J Psychiatry Neurosci, 34, 41
  48. Millet, 2010, Psychiatric indications of deep brain stimulation, Bull Acad Natl Med, 194, 583
  49. Milner, 1998, Hippocampal alpha2a-adrenergic receptors are located predominantly presynaptically but are also found postsynaptically and in selective astrocytes, J Comp Neurol, 395, 310, 10.1002/(SICI)1096-9861(19980808)395:3<310::AID-CNE4>3.0.CO;2-5 · DOI
  50. Mongeau, 2010, 5–HT2C receptor activation prevents stress-induced enhancement of brain 5-HT turnover and extracellular levels in the mouse brain: modulation Modulation by chronic paroxetine treatment, J Neurochem, 115, 438, 10.1111/j.1471-4159.2010.06932.x · DOI
  51. Mnie-Filali, 2011, Pharmacological blockade of 5-HT7 receptors as a putative fast acting antidepressant strategy, Neuropsychopharmacology, 36, 1275, 10.1038/npp.2011.13 · DOI
  52. Montgomery, 1994, Selective serotonin reuptake inhibitors: meta-analysis of discontinuation rates, Int Clin Psychopharmacol, 9, 47, 10.1097/00004850-199400910-00008 · DOI · Paper page
  53. Oades, 1987, Ventral tegmental (A10) system: neurobiology. 1. Anatomy and connectivity, Brain Res, 434, 117, 10.1016/0165-0173(87)90011-7 · DOI · Paper page
  54. Ordway, 2003, Elevated agonist binding to alpha 2-adrenoceptors in the locus coeruleus in major depression, Biol Psychiatry, 53, 315, 10.1016/S0006-3223(02)01728-6 · DOI
  55. Owen, 2011, Vilazodone: a new treatment option for major depressive disorder, Drugs Today (Barc), 47, 531, 10.1358/dot.2011.47.7.1622076 · doi:10.1358/dot.2011.47.7.1622076
  56. Owens, 2001, Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine, Biol Psychiatry, 50, 345, 10.1016/S0006-3223(01)01145-3 · DOI · Paper page
  57. Page, 2002, Behavioral and neurochemical effects of 5-{4-[4-(5-cyano-3indolyl)-butyl)-butyl]-1-piperazinyl}-benzofuran-2-carboxamide (EMD 68843): a combined selective inhibitor of serotonin reuptake and 5-hydroxytryptamine 1A receptor partial agonist, J Pharmacol Exp Ther, 302, 1220, 10.1124/jpet.102.034280 · DOI
  58. Paizanis, 2007, Life-long hippocampal neurogenesis: environmental, pharmacological and neurochemical modulations, Neurochem Res, 32, 1762, 10.1007/s11064-007-9330-0 · DOI
  59. Pandey, 2002, Higher expression of serotonin 5-HT2A receptors in the postmortem brains of teenage suicide victims, Am J Psychiatry, 159, 419, 10.1176/appi.ajp.159.3.419 · DOI · Paper page
  60. Parsey, 2006, Higher 5-HT1A receptor binding potential during a major depressive episode predicts poor treatment response: preliminary data from a naturalistic study, Neuropsychopharmacology, 31, 1745, 10.1038/sj.npp.1300992 · DOI · Paper page
  61. Parsey, 2006, Altered serotonin 1A binding in major depression: a [carbonyl-C-11]WAY100635 positron emission tomography study, Biol Psychiatry, 59, 106, 10.1016/j.biopsych.2005.06.016 · DOI · Paper page
  62. Pehrson, 2012, Lu AA21004, a novel multimodal antidepressant, produces regionally selective increases of multiple neurotransmitters – a rat microdialysis and electrophysiological study, Eur Neuropsychopharmacol, 23, 133, 10.1016/j.euroneuro.2012.04.006 · DOI · Paper page
  63. Piñeyro, 1999, Autoregulation of serotonin neurons: role in antidepressant drug action, Pharmacol Rev, 51, 533
  64. Pitchot, 2005, 5-Hydroxytryptamine 1A receptor, major depression, and suicidal behavior, Biol Psychiatry, 58, 854, 10.1016/j.biopsych.2005.05.042 · DOI
  65. Pitchot, 2004, Hormonal and temperature responses to flesinoxan in normal volunteers: an antagonist study, Eur Neuropsychopharmacol, 14, 151, 10.1016/S0924-977X(03)00108-1 · DOI
  66. Portella, 2011, Can we really accelerate and enhance the selective serotonin reuptake inhibitor antidepressant effect? A randomized clinical trial and a meta-analysis of pindolol in nonresistant depression, J Clin Psychiatry, 72, 962, 10.4088/JCP.09m05827blu · DOI
  67. Price, 2012, Neural circuits underlying the pathophysiology of mood disorders, Trends Cogn Sci, 16, 61, 10.1016/j.tics.2011.12.011 · DOI · Paper page
  68. Riad, 2000, Somatodendritic localization of 5-HT1A and preterminal axonal localization of 5-HT1B serotonin receptors in adult rat brain, J Comp Neurol, 417, 181, 10.1002/(SICI)1096-9861(20000207)417:2<181::AID-CNE4>3.0.CO;2-A · DOI · Paper page
  69. Richardson-Jones, 2010, 5-HT1A autoreceptor levels determine vulnerability to stress and response to antidepressants, Neuron, 65, 40, 10.1016/j.neuron.2009.12.003 · DOI · Paper page
  70. Richelson, 2010, New antipsychotic drugs: how do their receptor-binding profiles compare?, J Clin Psychiatry, 71, 1243, 10.4088/JCP.10ac06470yel · DOI
  71. Rosel, 2000, Altered 5-HT2A binding sites and second messenger inositol trisphosphate (IP3) levels in hippocampus but not in frontal cortex from depressed suicide victims, Psychiatry Res, 99, 173, 10.1016/S0925-4927(00)00076-7 · DOI
  72. Rush, 2011, Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study, Am J Psychiatry, 168, 689, 10.1176/appi.ajp.2011.10111645 · DOI · Paper page
  73. Saleem, 2008, Complementary circuits connecting the orbital and medial prefrontal networks with the temporal, insular, and opercular cortex in the macaque monkey, J Comp Neurol, 506, 659, 10.1002/cne.21577 · DOI · Paper page
  74. Sánchez, 1999, Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding, Cell Mol Neurobiol, 19, 467, 10.1023/A:1006986824213 · DOI · Paper page
  75. Sari, 1999, Cellular and subcellular localization of 5-hydroxytryptamine1B receptors in the rat central nervous system: immunocytochemical, autoradiographic and lesion studies, Neuroscience, 88, 899, 10.1016/S0306-4522(98)00256-5 · DOI · Paper page
  76. Schramm, 2001, The alpha(2a)-adrenergic receptor plays a protective role in mouse behavioral models of depression and anxiety, J Neurosci, 21, 4875, 10.1523/JNEUROSCI.21-13-04875.2001 · DOI · Paper page
  77. Scorza, 2011, Preclinical and clinical characterization of the selective serotonin-1A receptor antagonist DU-125530 for antidepressant treatment, Br J Pharmacol, 167, 1021, 10.1111/j.1476-5381.2011.01770.x · DOI · Paper page
  78. Seletti, 1995, Serotonin1A receptor activation by flesinoxan in humans. Body temperature and neuroendocrine responses, Neuropsychopharmacology, 13, 93, 10.1016/0893-133X(95)00025-9 · DOI
  79. Seminowicz, 2004, Limbic-frontal circuitry in major depression: a path modeling metanalysis, Neuroimage, 22, 409, 10.1016/j.neuroimage.2004.01.015 · DOI · Paper page
  80. Shopsin, 1975, Use of synthesis inhibitors in defining a role for biogenic amines during imipramine treatment in depressed patients, Psychopharmacol Commun, 1, 239
  81. Shopsin, 1976, Parachlorophenylalanine reversal of tranylcypromine effects in depressed patients, Arch Gen Psychiatry, 33, 811, 10.1001/archpsyc.1976.01770070041003 · DOI · Paper page
  82. Shimon, 1997, Reduced frontal cortex inositol levels in postmortem brain of suicide victims and patients with bipolar disorder, Am J Psychiatry, 154, 1148, 10.1176/ajp.154.8.1148 · DOI
  83. Stockmeier, 1998, Increase in serotonin-1A autoreceptors in the midbrain of suicide victims with major depression - postmortem evidence for decreased serotonin activity, J Neurosci, 18, 7394, 10.1523/JNEUROSCI.18-18-07394.1998 · DOI · Paper page
  84. Svenningsson, 2006, Alterations in 5-HT1B receptor function by p11 in depression-like states, Science, 311, 77, 10.1126/science.1117571 · DOI · Paper page
  85. Szabo, 2002, Effects of serotonin (5-hydroxytryptamine, 5-HT) reuptake inhibition plus 5–HT2A receptor antagonism on the firing activity of norepinephrine neurons, J Pharmacol Exp Ther, 302, 983, 10.1124/jpet.102.033282 · DOI
  86. Trivedi, 2008, Clinical evidence and potential neurobiological underpinnings of unresolved symptoms of depression, J Clin Psychiatry, 69, 246, 10.4088/JCP.v69n0211 · DOI · Paper page
  87. Turcotte, 2001, Assessment of the serotonin and norepinephrine reuptake blocking properties of duloxetine in healthy subjects, Neuropsychopharmacology, 24, 511, 10.1016/S0893-133X(00)00220-7 · DOI
  88. Turecki, 1999, Prediction of level of serotonin 2A receptor binding by serotonin receptor 2A genetic variation in postmortem brain samples from subjects who did or did not commit suicide, Am J Psychiatry, 156, 1456, 10.1176/ajp.156.9.1456 · DOI · Paper page
  89. Vincent, 2004, Clinical assessment of norepinephrine transporter blockade through biochemical and pharmacological profiles, Circulation, 109, 3202, 10.1161/01.CIR.0000130847.18666.39 · DOI · Paper page
  90. Weaver, 2004, Epigenetic programming by maternal behavior, Nat Neurosci, 7, 847, 10.1038/nn1276 · DOI · Paper page
  91. Westrich, 2012, In vitro and in vivo effects of the multimodal antidepressant vortioxetine (Lu AA21004) at human and rat targets, Int J Psychiatry Clin Pract, 16, 47
  92. Zhang, 2005, Loss-of-function mutation in tryptophan hydroxylase-2 identified in unipolar major depression, Neuron, 45, 11, 10.1016/j.neuron.2004.12.014 · DOI · Paper page
  93. Zhu, 2011, Altered white matter integrity in first-episode, treatment-naïve young adults with major depressive disorder: a tract-based spatial statistics study, Brain Res, 1369, 223, 10.1016/j.brainres.2010.10.104 · DOI · Paper page
  94. Zhuang, 1999, Altered emotional states in knockout mice lacking 5-HT1A or 5-HT1B receptors, Neuropsychopharmacology, 21, 52S, 10.1016/S0893-133X(99)00047-0 · DOI · Paper page

Cited by

See all 594

Metadata

Authors
Hamon, M., & Blier, P.
Venue
Progress in Neuro-Psychopharmacology and Biological Psychiatry
Publisher
Elsevier BV
Published
2013-08
Volume
45
Pages
54-63
ISSN
0278-5846
Cited by
594
References
37
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Monoamine neurocircuitry in depression and strategies for new treatments. https://app.cochat.ai/papers/10.1016/j.pnpbp.2013.04.009
The paper
Hamon, M., & Blier, P. (2013). Monoamine neurocircuitry in depression and strategies for new treatments. Progress in Neuro-Psychopharmacology and Biological Psychiatry. https://doi.org/10.1016/j.pnpbp.2013.04.009

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.